The latest announcement is out from Genfit SA ( (GNFT) ).
On March 10, 2025, GENFIT announced the approval of amendments to the terms and conditions of its 2025 OCEANEs by bondholders, allowing the company to proceed with a Royalty Financing agreement with HCRx. This approval enables GENFIT to repurchase the 2025 OCEANEs and pay a consent fee to holders, with key dates set for March and April 2025. The unanimous approval of the resolutions by bondholders marks a significant step for GENFIT, potentially impacting its financial strategy and stakeholder interests.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on improving the lives of patients with rare and life-threatening liver diseases. With a strong foundation in liver disease research and development, GENFIT has a diverse and expanding R&D portfolio, particularly targeting Acute-on-Chronic Liver Failure (ACLF) and other serious diseases such as cholangiocarcinoma and urea cycle disorder. The company is headquartered in Lille, France, and has offices in Paris, Zurich, and Cambridge, MA, USA. GENFIT is listed on the Nasdaq Global Select Market and Euronext in Paris.
YTD Price Performance: -4.70%
Average Trading Volume: 8,791
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $186.3M
For detailed information about GNFT stock, go to TipRanks’ Stock Analysis page.